Blindness News and Research

RSS

Aerie Pharmaceuticals closes $30 million Series B financing

Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing.

7 Mar 2011

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

The National Eye Institute and Food and Drug Administration are sponsoring a conference to determine how functional vision-related endpoints for clinical trials of visual prostheses will be analyzed and correlated with objective measures of visual acuity, visual fields and contrast sensitivity.

2 Mar 2011

Research uncovers new details about protein interactions in retina

Science fiction novelist and scholar Issac Asimov once said, "The most exciting phrase to hear in science, the one that heralds new discoveries, is not 'Eureka!' but 'That's funny.' " This recently rang true for an international team of researchers when they observed something they did not expect.

1 Mar 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

New community partnership launched to provide free vision care services for Akron-area children

Davis Vision, Prevent Blindness Ohio and Summa Hospital's Ophthalmology Department have launched an ongoing community partnership to provide needy Akron-area children with free vision care services.

22 Feb 2011

Statin drug may help prevent blindness in diabetics

New University of Georgia research has found that a statin drug that is often known by the brand-name Lipitor may help prevent blindness in people with diabetes.

17 Feb 2011

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

A readily available, inexpensive drug therapy showed a significant benefit in treating premature infants with the worst and historically most difficult-to-treat cases of retinopathy of prematurity.

17 Feb 2011

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor Pharmaceutical Corp., today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

15 Feb 2011

International agriculture conference highlights need to connect health, agriculture

Participants at the recent three-day International Conference on Leveraging Agriculture for Improving Nutrition and Health in New Delhi, India, highlighted the broken links between health and agriculture, IRIN reports (2/14).

15 Feb 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

Study explores levels of burden and depression in caregivers with sensory impairment

When a person experiences impairment or declining health, caregiving typically falls to a family member, most often a spouse. This increased burden can cause burnout, stress, and illness in the caregiver. The health care system focuses first on the client and provides little support for the caregiver.

14 Feb 2011

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

QLT Inc. today announced that QLT091001, an oral synthetic retinoid, has received positive opinions for two distinct Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for the treatment of the inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

10 Feb 2011

New insight into AMD related blindness

more than 50 million worldwideA new study in the journal Nature has reported the pathology of blindness caused by age-related macular degeneration or AMD. This condition affects more than 50 million worldwide and is incurable. The researchers report that when an enzyme known as DICER1 stops functioning AMD starts to develop.

8 Feb 2011

Researchers discover molecular mechanism implicated in geographic atrophy

A team of researchers, led by University of Kentucky ophthalmologist Dr. Jayakrishna Ambati, has discovered a molecular mechanism implicated in geographic atrophy, the major cause of untreatable blindness in the industrialized world.

6 Feb 2011

Study finds 24% of Spanish drivers have some vision problem

One in four Spanish drivers has a vision problem that affects their driving ability. This is the finding of a study commissioned by the association Visión y Vida in collaboration with the RACC to Aurora Torrents and Jaume Escofet, professors at EUOOT. The aim of the study is to provide objective information on the eyesight of Spanish drivers.

5 Feb 2011

UM researchers find genetic cause of retinitis pigmentosa

Researchers led by geneticists at the University of Miami Miller School of Medicine have identified a new gene that causes retinitis pigmentosa, a form of blindness, ending one South Florida family's nearly 20-year search for what caused three of their four children to lose their sight.

4 Feb 2011

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.

4 Feb 2011

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.

4 Feb 2011

Loyola opens Comprehensive Diabetes Care Clinic in Hickory Hills

Untreated or poorly managed diabetes can cause severe health complications such as kidney failure, blindness, heart disease, stroke and nerve damage. To help diabetic patients more easily care for their condition, Loyola has opened the Comprehensive Diabetes Care Clinic at Loyola Center for Health at Hickory Hills.

1 Feb 2011

Blindness News and Research

Aerie Pharmaceuticals closes $30 million Series B financing

NEI/FDA conference to analyze functional vision outcomes from clinical trials of visual prostheses

Research uncovers new details about protein interactions in retina

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

New community partnership launched to provide free vision care services for Akron-area children

Statin drug may help prevent blindness in diabetics

Inexpensive drug therapy shows promise in treating premature infants with childhood blindness

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

International agriculture conference highlights need to connect health, agriculture

Phase III RISE study of Lucentis for DME meets primary endpoint

Study explores levels of burden and depression in caregivers with sensory impairment

EMA grants QLT positive opinions for Orphan Drug Designation of QLT091001 to treat inherited blindness

New insight into AMD related blindness

Researchers discover molecular mechanism implicated in geographic atrophy

Study finds 24% of Spanish drivers have some vision problem

UM researchers find genetic cause of retinitis pigmentosa

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME

Loyola opens Comprehensive Diabetes Care Clinic in Hickory Hills

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News